Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
    May 24, 2022

    US FDA IDE Pre-Submission Meeting Summary

    The Vivos team felt that our meeting with the US FDA on 5/20/22 was a significant positive turning point in the FDA review process.  We proposed an additional short-term animal test to prove beyond any doubt that RadioGel™ can deliver a precise dose of therapeutic radiation and does not migrate from the tumor site.  We now have a clear path forward with the review team toward obtaining the IDE needed for the first in human clinical trials.


    Eight of the eleven FDA staff that reviewed our original IDE submission were new and not familiar with RadioGel™. They resurfaced legacy questions on dosimetry and the potential for migration which we have repeatedly addressed, but we’ve realized that another animal test is the most efficient means to answer those questions once and for all.  We agreed to provide the detailed test plan in another submission and the agency agreed to expedite the schedule for their review. This costs time, but helps ensure that they will accept the results.


    Since we anticipated this outcome, we have been in detailed discussions with Johns Hopkins University to perform the animal testing. During the meeting we presented a detailed outline of the proposed testing to obtain interim feedback. The FDA agreed with our outline and provided initial feedback on what they expect to see in the detailed test plan.


    The test is straight forward. We will induce VX-2 tumors in rabbits and then measure the activity over time using PET/CT to show, once again, that the Y-90 stays at the injection site. We will then euthanize the rabbits and quantitatively measure the remaining activity in the tumor using very sensitive counters and compare it to the starting activity corrected for decay.

     

    RadioGel™ will be a leader in Precision Radionuclide Therapy (PRnT). We have the highest Therapeutic Index of any device that the FDA has reviewed. This allows us to administer very high therapeutic doses with insignificant collateral damage to healthy tissue. We can treat lymph nodes with small amounts of Y-90 and achieve doses of 300 Gy or more.

    (Mike Korenko, Sc.D • CEO • President | May 24, 2022)

    I closed the meeting with a summary as follows:


    RadioGel™ will be a leader in Precision Radionuclide Therapy (PRnT). We have the highest Therapeutic Index of any device that the FDA has reviewed. This allows us to administer very high therapeutic doses with insignificant collateral damage to healthy tissue. We can treat lymph nodes with small amounts of Y-90 and achieve doses of 300 Gy or more.   
    RadioGel™ is intrinsically safe. Even if a significant amount of it activity migrated, which we know does not happen, the risk to the patient would be very low. We pointed out that the FDA has approved other brachytherapy products with much higher activity that is not fully contained. One of the side effects listed on the product label is occasional death.


    Finally, we believe that RadioGel™ should have a broad indication for use as a device that allows administering precision radionuclides to any tumor. It is our intent to demonstrate the safety and effectiveness of RadioGel ™in thyroid cancer therapy and then follow up with additional data to expand the indications for use to other tumor types and anatomic locations.

     

    Michael K. Korenko, Sc.D. – President & CEO

     

    CONTACT:
    Vivos Inc.
    Michael K. Korenko, Sc.D.
    President & CEO
    MKorenko@RadioGel.com

     

    tagPlaceholderTags:

    Vivos, Inc.

    Precision Radionuclide Therapy (PRnT)

    OTCQB: RDGL

    contact: info@radiogel.com


    Home Page Cover Image: 

     

    Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

     

    Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application(s)


    Precision Radionuclide Therapy (PRnT)


    Vivos Inc.
     - (OTCQB: RDGL) Investor Relations 

    Contact

     

    Main colors
       bg-primary
       bg-primary-light
       bg-primary-dark
       bg-secondary
       bg-secondary-dark
    Template sections
       body
       top-header
       header
       content
    Footer Styles
       background
       text color
       link color
       horizontal line
    Buttons
       style 1
       style 2
       style 3
    Other elements
      social icons
      navigation color
      subnav background
    Mobile navigation
       background color
       navigation color
    Template configurations
    has-right-nav g-font
    navigation styles
    size-15 weight-400 snip-nav
    content styles
    form-white
    footer styles
    o-form color-white
    Typography
    Heading H1
    weight-600
    Heading H2
    weight-600
    Heading H3
    weight-600
    Buttons
    weight-600 is-uppercase
    Animations

    Note:
    All changes made here will be applied to your entire website.
    is-switcher admin-only

    RadioGel™ Logo

    Precision Radionuclide Therapy (PRnT)

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top